What are the potential benefits of DSIP?

The potential benefits studied in humans include changes in sleep measures, ACTH levels, chronic pain scores and withdrawal symptoms. Confidence is very low. The trials were generally small, old, brief and often uncontrolled, and their results were mixed. These findings support further study rather than a promise that a patient will sleep better, feel less pain or have a lower stress response.

Does DSIP improve deep sleep?

The evidence is uncertain. Early studies reported improvements in sleep efficiency, sleep latency or total sleep time, but later placebo-controlled work found weak effects and no improvement in most measures, including subjective sleep quality. The studies were also tiny and mostly used intravenous administration. They do not establish that a modern compounded formulation reliably increases deep sleep.

Does DSIP lower cortisol?

Not in the small controlled human study that directly measured it. Researchers found a reduction in ACTH-like immunoreactivity after a single intravenous infusion in 11 healthy men, but plasma cortisol was unaffected and urinary cortisol did not differ from saline. Describing that result as a general cortisol-lowering or stress-relief benefit would go beyond the evidence.

What happened at the FDA's 2026 DSIP review?

The Pharmacy Compounding Advisory Committee recommended against adding DSIP free base and acetate to the Section 503A bulk drug substances list. On July 24, 2026, each vote was 6 yes, 7 no and 1 abstention. The recommendation is nonbinding and was not a final agency rule; prescribing a compounded formulation remains a decision for a licensed provider and patient.

Can DSIP help with chronic pain or withdrawal?

Only preliminary signals exist. A seven-person uncontrolled pain pilot reported lower scores in six participants, while an open-label inpatient report described improvement during alcohol or opioid withdrawal. Neither had the controls needed to establish cause and effect. Withdrawal requires appropriate medical supervision, and these old studies do not support substituting DSIP for established care.

DSIP Benefits: What the Human Evidence Shows

DSIP benefits are possible rather than established. The most direct human evidence concerns sleep: several tiny studies from the 1980s reported better sleep measures, while later controlled work found only weak effects. Outside sleep, single small studies reported changes in ACTH, chronic pain scores and withdrawal symptoms. None is enough to treat DSIP as a settled therapy for insomnia, pain or withdrawal.

The name delta sleep-inducing peptide can sound like a conclusion. It is not one. What DSIP is covers the compound's background; here, the useful question is what each claimed benefit rests on.

DSIP benefits are mostly preliminary

The evidence map is short, and its limitations matter as much as its positive results. Nearly all human treatment studies used intravenous DSIP, enrolled fewer than 20 people, or lacked a concurrent placebo group. Those findings do not automatically transfer to a modern compounded formulation or another route of administration.

Claimed benefit	Human evidence	Confidence
Better sleep	Several small trials, with positive and negative findings	Very low
Lower stress response	One 11-person study changed ACTH but not cortisol	Very low
Less chronic pain	One uncontrolled seven-person pilot	Very low
Milder withdrawal symptoms	Small or uncontrolled inpatient studies	Very low

This is a research signal, not a list of outcomes a patient should expect. The gap between those two ideas is the central fact about DSIP.

The sleep studies do not agree

The positive case begins with very small experiments. A 1981 double-blind crossover study in six healthy volunteers reported 59% more sleep during a 130-minute daytime observation period after an infusion, along with shorter sleep onset and better sleep efficiency that night (Schneider-Helmert et al., 1981). That was a physiological experiment, not evidence of durable insomnia treatment.

Other early reports were optimistic. Schneider-Helmert's 1987 study followed 14 people with chronic insomnia and reported improvements in sleep efficiency and daytime performance. Kaeser's 1984 open study treated seven people and reported normalized sleep in six during follow-up (Kaeser, European Neurology 1984). Neither result carries the certainty of a large, independently replicated trial.

The counterweight arrived in 1992. A double-blind study of 16 people with chronic insomnia found somewhat higher objective sleep efficiency and shorter sleep latency, but most measures—including subjective sleep quality—did not change. The authors judged the effects weak and concluded that short-term treatment was unlikely to offer major therapeutic benefit (Bes et al., Neuropsychobiology 1992).

Taken together, DSIP may influence sleep physiology in some settings, but the studies do not establish a reliable clinical benefit, a durable response or who is most likely to respond. They also predate current insomnia-trial standards by decades.

ACTH changed, but cortisol did not

Claims about stress usually trace to a randomized, double-blind crossover study in 11 healthy men. A single intravenous infusion reduced ACTH-like immunoreactivity for at least three hours compared with saline. Plasma cortisol followed its normal daily decline and was unaffected; urinary cortisol did not differ either (Bjartell et al., Psychoneuroendocrinology 1989).

That is a narrow neuroendocrine observation. It does not show that DSIP lowers cortisol, treats anxiety or improves resilience under everyday stress. Those broader claims outrun the human data.

The chronic-pain signal came from seven people

A 1984 pilot study included seven people with migraine or vasomotor headache, chronic tinnitus, or psychogenic pain attacks. Six reported lower pain levels after a series of intravenous injections (Larbig et al., European Neurology 1984).

There was no concurrent placebo arm, the diagnoses were mixed, and the sample was far too small to separate a treatment effect from symptom fluctuation, expectation or regression toward the mean. This study supports further investigation. It does not establish DSIP as a pain treatment.

Withdrawal findings were uncontrolled

The largest early report administered intravenous DSIP to 107 inpatients experiencing alcohol or opioid withdrawal. Investigators reported rapid improvement in many patients, but treatment was open-label and outcomes came from clinical observation rather than a blinded comparison (Dick et al., European Neurology 1984). A later seven-person opioid-withdrawal study was also open-label and called for placebo-controlled research.

Withdrawal can require urgent, supervised medical care. These reports do not support replacing established treatment, and they do not show that DSIP works for chronic pain simply because pain can occur during withdrawal.

What the July 2026 PCAC vote means

On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered emideltide—the formal name used for DSIP free base and acetate—for possible addition to the Section 503A bulk drug substances list. The committee voted 6 yes, 7 no and 1 abstention on each form, so it recommended against adding them. The FDA meeting page identifies chronic insomnia, narcolepsy and opioid withdrawal as the uses reviewed.

That vote was advice, not a final agency rule. FDA's own explanation says advisory-committee recommendations are nonbinding. It is neither proof that DSIP lacks every biological effect nor evidence that it works. It is a regulatory judgment about whether the record supported listing two bulk substances.

A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the provider. Through Promise, DSIP is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

What a responsible DSIP benefit claim sounds like

The defensible summary is that DSIP has been studied for sleep and several related neuroendocrine or symptom outcomes, with inconsistent and very low-certainty human evidence. A claim that it reliably produces deep sleep, lowers cortisol or relieves chronic pain is stronger than the published record.

A prescriber can put the evidence beside the reason for poor sleep, other medications, substance-use history and the risks of a compounded injectable. DSIP dosage explains how dosing decisions are framed; the reviewing prescriber sets the actual plan. At Promise, a licensed provider reviews every request and not everyone qualifies. The prescription process begins with compound-specific clinical screening, not a guaranteed order.